GSK plots regulatory filings for PBC itch after positive Phase 3 readout
GSK’s linerixibat helped reduce itch in patients with an autoimmune liver disease that affects the bile ducts, meeting its primary endpoint in a late-stage trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
